Publikationen T. Todenhoefer, MD, PhD

In zahlreichen Publikationen ist Herr Todenhoefer, MD, PhD, Studienpraxis Urologie, Nuertingen Urheber, Autor und Ko-Autor

2019

Walz S, Maas M, Stenzl A, Todenhöfer T.

Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review.

World J Mens Health. 2019 May 2. doi: 10.5534/wjmh.190044. [Epub ahead of print] Review.

Lutz SZ, Wagner R, Fritsche L, Peter A, Rettig I, Willmann C, Fehlert E, Martus P, Todenhöfer T, Stefan N, Fritsche A, Häring HU, Heni M.

Sex-Specific Associations of Testosterone With Metabolic Traits.

Front Endocrinol (Lausanne). 2019 Mar 13;10:90. doi: 10.3389/fendo.2019.00090. eCollection 2019.

Costa IAD, Hennenlotter J, Todenhöfer T, Neumann E, Deininger S, Aufderklamm S, Bedke J, Stenzl A, Rausch S.

Determination of Free-PSA (fPSA) and fPSA/PSA-Ratio Using A Point-of-Care Device.

Clin Lab. 2019 Jan 1;65(1). doi: 10.7754/Clin.Lab.2018.180710.

Todenhöfer T, Miernik A, Seiler R.

[High-throughput molecular analysis of urothelial carcinoma: potential clinical applications].

Aktuelle Urol. 2019 Feb;50(1):84-93. doi: 10.1055/a-0755-7284. Epub 2019 Feb 7. German.

Kretschmer A, Todenhöfer T.

Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?

Eur Urol Focus. 2019 Mar;5(2):114-116. doi: 10.1016/j.euf.2018.11.008. Epub 2018 Nov 24.

2018

Mathes J, Todenhöfer T.

Managing Toxicity of Intravesical Therapy.

Eur Urol Focus. 2018 Jul;4(4):464-467. doi: 10.1016/j.euf.2018.09.009. Epub 2018 Oct 25.

Stühler V, Maas JM, Bochem J, da Costa IA, Todenhöfer T, Stenzl A, Bedke J.

Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.

World J Urol. 2018 Oct 29. doi: 10.1007/s00345-018-2538-6. [Epub ahead of print]

Bedke J, Stühler V, Todenhöfer T, Stenzl A.

[Mode of action, new targets and potential biomarkers in modern immunotherapy].

Urologe A. 2018 Nov;57(11):1301-1308. doi: 10.1007/s00120-018-0787-z. Review. German.

Mathes J, Rausch S, Todenhöfer T, Stenzl A.

Trimodal therapy for muscle-invasive bladder cancer.

Expert Rev Anticancer Ther. 2018 Dec;18(12):1219-1229. doi: 10.1080/14737140.2018.1535314. Epub 2018 Oct 17. Review.

Maas M, Bedke J, Stenzl A, Todenhöfer T.

Can urinary biomarkers replace cystoscopy?

World J Urol. 2018 Oct 3. doi: 10.1007/s00345-018-2505-2. [Epub ahead of print]

Todenhöfer T, Seiler R, Stewart C, Moskalev I, Gao J, Ladhar S, Kamjabi A, Al Nakouzi N, Hayashi T, Choi S, Wang Y, Frees S, Daugaard M, Oo HZ, Fisel P, Schwab M, Schaeffeler E, Douglas J, Hennenlotter J, Bedke J, Gibb EA, Fazli L, Stenzl A, Black PC.

Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.

Mol Cancer Ther. 2018 Dec;17(12):2746-2755. doi: 10.1158/1535-7163.MCT-18-0107. Epub 2018 Sep 27.

Soria F, Krabbe LM, Todenhöfer T, Dobruch J, Mitra AP, Inman BA, Gust KM, Lotan Y, Shariat SF.

Molecular markers in bladder cancer.

World J Urol. 2019 Jan;37(1):31-40. doi: 10.1007/s00345-018-2503-4. Epub 2018 Sep 26.

da Costa IA, Hennenlotter J, Stühler V, Kühs U, Scharpf M, Todenhöfer T, Stenzl A, Bedke J.

Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis.

Urol Oncol. 2018 Oct;36(10):472.e21-472.e27. doi: 10.1016/j.urolonc.2018.06.010. Epub 2018 Aug 16.

Aufderklamm S, Hennenlotter J, Leidenberger P, Rausch S, Hohneder A, Kühs U, Maas M, Schwentner C, Bedke J, Stenzl A, Todenhöfer T.

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases.

Dis Markers. 2018 Jul 18;2018:1874598. doi: 10.1155/2018/1874598. eCollection 2018.

Deininger S, Haberstock L, Kruck S, Neumann E, da Costa IA, Todenhöfer T, Bedke J, Stenzl A, Rausch S.

Single-use versus reusable ureterorenoscopes for retrograde intrarenal surgery (RIRS): systematic comparative analysis of physical and optical properties in three different devices.

World J Urol. 2018 Dec;36(12):2059-2063. doi: 10.1007/s00345-018-2365-9. Epub 2018 Jun 5.

Maas M, Walz S, Stühler V, Aufderklamm S, Rausch S, Bedke J, Stenzl A, Todenhöfer T.

Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer.

Expert Rev Mol Diagn. 2018 May;18(5):443-455. doi: 10.1080/14737159.2018.1469979. Review.

Bier S, Hennenlotter J, Esser M, Mohrhardt S, Rausch S, Schwentner C, Maas M, Deininger S, Walz S, Bedke J, Stenzl A, Todenhöfer T.

Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?

Dis Markers. 2018 Jan 30;2018:5823870. doi: 10.1155/2018/5823870. eCollection 2018.

Deininger S, Hennenlotter J, Rausch S, Docktor K, Neumann E, da Costa IA, Bedke J, Stenzl A, Todenhöfer T.

No influence of smoking status on the performance of urine markers for the detection of bladder cancer.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1367-1373. doi: 10.1007/s00432-018-2639-z. Epub 2018 Apr 19.

Bedke J, Todenhöfer T, Stenzl A.

[Immune checkpoint inhibition in metastatic urothelial carcinoma].

Aktuelle Urol. 2018 Apr;49(2):178-186. doi: 10.1055/a-0581-4395. Epub 2018 Mar 27. German.

Russo GI, Bier S, Hennenlotter J, Beger G, Pavlenco L, van de Flierdt J, Hauch S, Maas M, Walz S, Rausch S, Bedke J, Morgia G, Stenzl A, Todenhöfer T.

Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.

BJU Int. 2018 Mar 15. doi: 10.1111/bju.14200. [Epub ahead of print]

Stühler V, Kruck S, Todenhöfer T, Stenzl A, Bedke J.

[Current guideline-oriented follow-up of small renal masses : Applied risk scores and future outlook].

Urologe A. 2018 Mar;57(3):300-306. doi: 10.1007/s00120-018-0586-6. Review. German.

Todenhöfer T, Struss WJ, Seiler R, Wyatt AW, Black PC.

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer.

Bladder Cancer. 2018 Jan 20;4(1):19-29. doi: 10.3233/BLC-170140. Review.

Russo GI, Cimino S, Giranio G, Regis F, Favilla V, Privitera S, Motta F, Caltabiano R, Stenzl A, Todenhöfer T, Morgia G.

Metabolic syndrome is not associated with greater evidences of proliferative inflammatory atrophy and inflammation in patients with suspected prostate cancer.

Urol Oncol. 2018 Feb 8. pii: S1078-1439(18)30012-7. doi: 10.1016/j.urolonc.2018.01.012. [Epub ahead of print]

To SQ, Kwan EM, Fettke HC, Mant A, Docanto MM, Martelotto L, Bukczynska P, Ng N, Graham LK, Parente P, Pezaro C, Mahon K, Horvath L, Todenhöfer T, Azad AA.

Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.

Eur Urol. 2018 Feb 2. pii: S0302-2838(18)30016-2. doi: 10.1016/j.eururo.2018.01.007. [Epub ahead of print]

Khalaf DJ, Avilés CM, Azad AA, Sunderland K, Todenhöfer T, Eigl BJ, Finch D, Le L, Atwell A, Keith B, Kollmannsberger C, Chi KN.

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Can Urol Assoc J. 2018 Feb;12(2):E47-E52. doi: 10.5489/cuaj.4600. Epub 2017 Dec 1.

Lutz SZ, Todenhöfer T, Wagner R, Hennenlotter J, Ferchl JM, Scharpf MO, Martus P, Staiger H, Fritsche A, Stenzl A, Häring HU, Heni M.

Higher prevalence of lymph node metastasis in prostate cancer in patients with diabetes.

Endocr Relat Cancer. 2018 Mar;25(3):L19-L22. doi: 10.1530/ERC-17-0465. Epub 2018 Jan 12. No abstract available.

Hegemann M, Maas M, Rausch S, Walz S, Bedke J, Stenzl A, Todenhöfer T.

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer.

Asian J Androl. 2017 Dec 29. doi: 10.4103/aja.aja_59_17. [Epub ahead of print] Review.

Lutz SZ, Hennenlotter J, Scharpf MO, Sailer C, Fritsche L, Schmid V, Kantartzis K, Wagner R, Lehmann R, Berti L, Peter A, Staiger H, Fritsche A, Fend F, Todenhöfer T, Stenzl A, Häring HU, Heni M. Androgen receptor overexpression in prostate cancer in type 2 diabetes.

Mol Metab. 2018 Feb;8:158-166. doi: 10.1016/j.molmet.2017.11.013. Epub 2017 Dec 5.

Deininger S, Todenhöfer T, Hennenlotter J, Gerber V, Schwarz J, Bedke J, Schwentner C, Stenzl A, Rausch S.

Impact of variant microscopic interpretation of the uCyt+ immunocytological urine test for the detection of bladder cancer.

Diagn Cytopathol. 2018 Feb;46(2):111-116. doi: 10.1002/dc.23857. Epub 2017 Nov 8.

Mischinger J, Abdelhafez MF, Rausch S, Todenhöfer T, Neumann E, Aufderklamm S, Stenzl A, Gakis G.

Perioperative morbidity, bowel function and oncologic outcome after radical cystectomy and ileal orthotopic neobladder reconstruction: Studer-pouch versus I-pouch.

Eur J Surg Oncol. 2018 Jan;44(1):178-184. doi: 10.1016/j.ejso.2017.10.208. Epub 2017 Oct 20.

Rossnagl S, Ghura H, Groth C, Altrock E, Jakob F, Schott S, Wimberger P, Link T, Kuhlmann JD, Stenzl A, Hennenlotter J, Todenhöfer T, Rojewski M, Bieback K, Nakchbandi IA.

A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow.

Cancer Res. 2018 Jan 1;78(1):129-142. doi: 10.1158/0008-5472.CAN-16-3507. Epub 2017 Oct 24.

Stühler V, Kruck S, Hegemann M, Notohamiprodjo M, Todenhöfer T, Kröger N, Stenzl A, Bedke J.

[TKI 2.0 - changes in the medical treatment of renal cell carcinoma].

Urologe A. 2018 Mar;57(3):314-322. doi: 10.1007/s00120-017-0496-z. Review. German.

2017

Maas M, Hegemann M, Rausch S, Bedke J, Stenzl A, Todenhöfer T.

Circulating tumor cells and their role in prostate cancer.

Asian J Androl. 2017 Aug 22. doi: 10.4103/aja.aja_29_17. [Epub ahead of print] Review.

Vandekerkhove G*, Todenhöfer T*, Annala M*, Struss WJ, Wong A, Beja K, Ritch E, Brahmbhatt S, Volik SV, Hennenlotter J, Nykter M, Chi KN, North S, Stenzl A, Collins CC, Eigl BJ, Black PC, Wyatt AW.

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.

Clin Cancer Res. 2017 Nov 1;23(21):6487-6497. doi: 10.1158/1078-0432.CCR-17-1140. Epub 2017 Jul 31. * contributed equally

Todenhöfer T, Hennenlotter J, Keller G, Neumann T, Stenzl A, Bedke J.

Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer.

Prostate. 2017 Sep;77(12):1251-1258. doi: 10.1002/pros.23384. Epub 2017 Jul 20.

Seiler R, Black PC, Thalmann G, Stenzl A, Todenhöfer T.

Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer? Urol Oncol. 2017 Mar 10. pii: S1078-1439(17)30059-5. doi: 10.1016/j.urolonc.2017.01.024.

Werner S, Stenzl A, Pantel K, Todenhöfer T.

Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells. Adv Exp Med Biol. 2017;994:205-228. doi: 10.1007/978-3-319-55947-6_11.

Hegemann M, Bedke J, Stenzl A, Todenhöfer T.

Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience.

Ther Adv Urol. 2017 Feb 6;9(3-4):81-88

Todenhöfer T, Black PC.

Editorial Comment.

J Urol. 2017 Jan;197(1):215. doi: 10.1016/j.juro.2016.08.125.

Mischinger J, Guttenberg LP, Hennenlotter J, Gakis G, Aufderklamm S, Rausch S, Neumann E, Bedke J, Kruck S, Schwentner C, Stenzl A, Todenhöfer T.

Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization.

J Cancer Res Clin Oncol. 2017 Apr;143(4):677-685. doi: 10.1007/s00432-016-2310-5. Epub 2016 Dec 2.

Seiler R, Oo HZ, Tortora D, Clausen TM, Wang CK, Kumar G, Pereira MA, Ørum-Madsen MS, Agerbæk MØ, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, Douglas J, Todenhöfer T, Esfandnia S, Battsogt D, Babcook JS, Al-Nakouzi N, Crabb SJ, Moskalev I, Kiss B, Davicioni E, Thalmann GN, Rennie PS, Black PC, Salanti A, Daugaard M.

An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.

Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30232-4. doi: 10.1016/j.eururo.2017.03.021.

Seiler R, Ashab HA, Erho N, van Rhijn BW, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Eur Urol. 2017 Apr 5. pii: S0302-2838(17)30251-8

Kruck S, Hennenlotter J, Amend B, Geiger M, Filipova E, Neumann T, Stühler V, Schubert T, Todenhöfer T, Rausch S, Huettig F, Stenzl A, Bedke J.

Chronic Periodontitis Does Not Impact Serum Levels of Prostate-specific Antigen.

Anticancer Res. 2017 Jun;37(6):3163-3167

Bier S, Aufderklamm S, Todenhöfer T, Kruck S, Schuster K, Rausch S, Othman A, Notohamiprodjo M, Nikolaou K, Schwentner C, Stenzl A, Bier G, Bedke J.

Prediction of Postoperative Risks in Laparoscopic Partial Nephrectomy Using RENAL, Mayo Adhesive Probability and Renal Pelvic Score.

Anticancer Res. 2017 Mar;37(3):1369-1373.

Neumann E, Hennenlotter J, Todenhöfer T, Scharpf M, Neumann T, Schilling D, Stenzl A, Bedke J.

The Value and Evaluability of the PCA3 Urine Assay in Prostate Carcinoma is Independent of the Tumor Localization. Adv Ther. 2017 Apr;34(4):966-974

Anselmo Da Costa I, Rausch S, Kruck S, Todenhöfer T, Stenzl A, Bedke J.

Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?

Expert Rev Anticancer Ther. 2017 Apr;17(4):357-368. doi: 10.1080/14737140.2017.1292138. Epub 2017 Feb 20. Review.

2016

Todenhöfer T, Park S, Duffy S, Deng X, Jin C, Abdi H, Ma H, Black PC

Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer.

Urol Oncol. 2016 Sep 19. pii: S1078-1439(16)30121-1 (IF=2.77)

Todenhöfer T, Azad A, Stewart C, Gao J, Eigl BJ, Gleave ME, Joshua AM, Black PC, Chi KN.

AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to Abiraterone acetate.

J Urol. 2016 Jul 16. pii: S0022-5347(16)30860-6. (IF=4.7)

Todenhöfer T, Hennenlotter J, Dorner N, Kühs U, Aufderklamm S, Rausch S, Bier S, Mischinger J, Schellbach D, Hauch S, Feniuk N, Bedke J, Gakis G, Stenzl A, Schwentner C.

Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients.

J Cancer Res Clin Oncol. 2016 Feb 24. [Epub ahead of print] (IF=3.08)

Todenhöfer T., Seiler R. Editorial Comment to Robotic transmural ablation of bladder tumors using high-intensity focused ultrasound: Experimental study.

Int J Urol. 2016, doi: 10.1111/iju.13098. [Epub ahead of print] (IF=2.41)

Rausch S, Hennenlotter J, Scharpf M, Teepe K, Kühs U, Aufderklamm S, Bier S, Mischinger J, Gakis G, Stenzl A, Schwentner C, Todenhöfer T.

Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma.

J Cancer Res Clin Oncol 2016/ Epub ahead of print (IF 3.08)

Hegemann M, Stenzl A, Bedke J, Chi KN, Black PC, Todenhöfer T.

Liquid biopsy: ready to guide therapy in advanced prostate cancer?

BJU Int. 2016 Jul 19. doi: 10.1111/bju.13586.

Rausch S, Hennenlotter J, Wiesenreiter J, Hohneder A, Heinkele J, Schwentner C, Stenzl A, Todenhöfer T.

Assessment of a new point-of-care system for detection of prostate specific antigen.

BMC Urology / 16(1):4 (IF=1.41)

Bier S, Hennenlotter J, Rausch S, Aufderklamm S, Martzog JC, Stenzl A, Schwentner C, Todenhöfer T.

Return to Work and Normal Daily Life Activity after Open and Robot-Assisted Radical Prostatectomy - A Single Surgeon Analysis.

Urologia Internationalis / Epub ahead of print (IF=1.42)

Chedgy EC, Douglas J, Wright JL, Seiler R, van Rhijn BW, Boormans J, Todenhöfer T, Dinney CP, Collins CC, Van der Heijden MS, Black PC.

Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.

Urol Oncol. 2016 Oct;34(10):469-76. (IF=2.92)

Schmitz-Dräger C, Bonberg N, Pesch B, Todenhöfer T, Sahin S, Behrens T, Brüning T, Schmitz-Dräger BJ.

Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.

Urol Oncol. 2016 Oct;34(10):452-9.

Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA.

Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines.

Urol Oncol. 2016 Oct;34(10):437-51 (IF=2.91)

Park ES, Jin C, Guo Q, Ang RR, Duffy SP, Matthews K, Azad A, Abdi H, Todenhöfer T, Bazov J, Chi KN, Black PC, Ma H.

Continuous Flow Deformability-Based Separation of Circulating Tumor Cells Using Microfluidic Ratchets.

Small. 2016 Feb 24. doi: 10.1002/smll.201503639. [Epub ahead of print] (IF=8.36)

Gakis G, Efstathiou JA, Daneshmand S, Keegan KA, Clayman RH, Hrbacek J, Ali-El-Dein B, Zaid HB, Schubert T, Mischinger J, Todenhöfer T, Galland S, Olugbade K Jr, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Morgan TM.

Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma.

Urol Int. 2016;97(2):134-41 (IF=1.31)

2015

Todenhöfer T, Hennenlotter J, Guttenberg P, Mohrhardt S, Kuehs U, Esser M, Aufderklamm S, Bier S, Harland N, Rausch S, Gakis G, Stenzl A, Schwentner C.

Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.

BMC Cancer. 2015 Mar 19;15:155. (IF 3.3)

Todenhöfer T, Hennenlotter J, Faber F, Wallwiener D, Schilling D, Kühs U, Aufderklamm S, Bier S, Mischinger J, Gakis G, Fehm T, Stenzl A, Schwentner C.

Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer.

Prostate. 2015 Jan 13. doi: 10.1002/pros.22947. [Epub ahead of print] (IF 3.56)

Todenhöfer T, Stenzl A, Hofbauer LC, Rachner TD

Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies

Int J Endocrinology, Volume 2015 (2015), Article ID 838202, (IF 1.94)

Gakis G, Todenhöfer T (contributed equally), Braun M, Fend F, Stenzl A, Perner S.

Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder.

Scand J Urol. 2015 Apr 28:1-6. [Epub ahead of print] (IF=1.24)

Rausch S, Hennenlotter J, Teepe K, Kuehs U, Aufderklamm S, Bier S, Mischinger J, Gakis G, Stenzl A, Schwentner C, Todenhöfer T.

Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.

Urol Oncol. 2015 Jul 29. pii: S1078-1439(15)00295-1 (IF 2.77)

Semilia M, Hennenlotter J, Pavone C, Bischoff T, Kühs U, Gakis G, Bedke J, Stenzl A, Schwentner C, Todenhöfer T.

Expression patterns and prognostic role of transketolase-like 1 in muscle-invasive bladder cancer.

World J Urol. 2015 Jan 9. [Epub ahead of print] (IF 2.66)

Qin X, Park S, Duffy SP, Matthews K, Ang RR, Todenhöfer T, Abdi H, Azad A, Bazov J, Chi KN, Black PC, Ma H.

Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell traps.

Lab Chip. 2015 May 5;15(10):2278-86. (IF 6.15)

Schubert T, Todenhöfer T, Mischinger J, Schwentner C, Renninger M, Stenzl A, Gakis G .The prognostic role of pre-cystectomy hemoglobin levels in patients with invasive bladder cancer. World J Urol. / Epub ahead of print (IF=2.66)

Gakis G, Morgan TM, Daneshmand S, Keegan KA, Todenhoefer T, Mischinger J, Schubert T, Zaid HB, Hrbacek J, Ali-El-Dein B, Clayman RH, Galland S, Olugbade K Jr, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Efstathiou JA.

Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: Results of the International Collaboration on Primary Urethral Carcinoma.

Ann Oncol. 2015 May 12. pii: mdv230. [Epub ahead of print] (IF=7.04)

Gakis G, Morgan TM, Efstathiou JA, Keegan KA, Mischinger J, Todenhoefer T, Schubert T, Zaid HB, Hrbacek J, Ali-El-Dein B, Clayman RH, Galland S, Olugbade K Jr, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Daneshmand S.

Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma.

World J Urol. 2015 May 17. [Epub ahead of print] (IF 2.66)

Schwentner C, Sim A, Balbay MD, Todenhöfer T, Aufderklamm S, Halalsheh O, Mischinger J, Böttge J, Rausch S, Bier S, Stenzl A, Gakis G, Canda AE.

Robot-assisted radical cystectomy and intracorporeal neobladder formation: on the way to a standardized procedure.

World J Surg Oncol. 2015 Jan 6;13(1):3. doi: 10.1186/1477-7819-13-3. (IF 1.41)

Sim A, Balbay MD, Todenhöfer T, Aufderklamm S, Halalsheh O, Mischinger J, Böttge J, Rausch S, Bier S, Stenzl A, Gakis G, Schwentner C, Canda AE.

Robot-assisted radical cystectomy and intracorporeal urinary diversion - safe and reproducible?

Cent European J Urol. 2015;68(1):18-23

Gakis G, Ngamsri T, Rausch S, Mischinger J, Todenhöfer T, Schwentner C, Schmid MA, Hassan FA, Renninger M, Stenzl A.

Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy.

World J Urol. 2015 Jan 17. [Epub ahead of print] (IF 2.66)

Bier S, Sim A, Balbay D, Todenhöfer T, Aufderklamm S, Halalsheh O, Mischinger J, Böttge J, Rausch S, Stenzl A, Gakis G, Canda E, Schwentner C.

[Treatment of invasive bladder cancer : Robot-assisted radical cystectomy and intracorporeal urinary diversion].

Urologe A. 2015 Jan;54(1):41-6. doi: 10.1007/s00120-014-3702-2. (IF=0.44)

Bier S, Todenhöfer T, Aufderklamm S, Hennenlotter J, Mischinger J, Sim A, Böttge J, Rausch S, Halalsheh O, Stenzl A, Gakis G, Schwentner C.

[Laparoscopic partial nephrectomy for renal tumors : Time for a new standard?]

Urologe A. 2015 Jan;54(1):41-6. (IF=0.44)

Sim A, Todenhöfer T, Mischinger J, Halalsheh O, Fahmy O, Boettge J, Rausch S, Bier S, Aufderklamm S, Liatsikos E, Stenzl A, Gakis G, Schwentner C.

Y Pouch Neobladder-A Simplified Method of Intracorporeal Neobladder After Robotic Cystectomy.

J Endourol. 2015 Apr;29(4):387-9. (IF=1.71)

2014

Todenhöfer T, Hennenlotter J ,Leidenberger P, Wald A, Hohneder A, Kühs U, Mischinger J, Aufderklamm S, Gakis G, Blumenstock G, Stenzl A, Schwentner C.

Serum RANKL levels predict biochemical recurrence in patients undergoing radical prostatectomy.

BJU Int. 2014 Jan;113(1):152-9 (IF 3.53)

Todenhöfer T, Hennenlotter J, Esser M, Mohrhardt S, Aufderklamm S, Böttge J, Rausch S, Mischinger J, Bier S, Gakis G, Kuehs U, Stenzl A, Schwentner C.

Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer.

Dis Markers. 2014;2014:973406. doi: 10.1155/2014/973406. Epub 2014 Dec 22

(IF 1.56)

Todenhöfer T, Schwentner C.

Editorial comment from Dr Todenhöfer and Dr Schwentner to recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.

Int J Urol. 2014 Oct;21(10):973. (IF 2.41)

Ritter R, Hennenlotter J, Kühs U, Hofmann U, Aufderklamm S, Blutbacher P, Deja A, Hohneder A, Gerber V, Gakis G, Stenzl A, Schwentner C, Todenhöfer T.

Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer.

Urol Oncol. 2014 Apr;32(3):337-44 (IF 2.77)

Gakis G, Fritsche HM, Hassan F, Kluth L, Miller F, Soave A, Otto W, Schwentner C, Todenhöfer T, Dahlem R, Burger M, Fisch M, Stenzl A, Aziz A, Rink M.

Prognostic relevance of postoperative platelet count in upper tract urothelial carcinoma after radical nephroureterectomy.

Eur J Cancer. 2014 Oct;50(15):2583-91. doi: 10.1016/j.ejca.2014.07.003. Epub 2014 Jul 31. (IF 5.42)

Mischinger J, Abdelhafez MF, Todenhöfer T, Schwentner C, Aufderklamm S, Stenzl A, Gakis G.

Quality of life outcomes after radical cystectomy: long-term standardized assessment of Studer Pouch versus I-Pouch.

World J Urol. 2014 Dec 11. [Epub ahead of print] (IF 2.66)

von Klot CA, Kramer MW, Böker A, Herrmann TR, Peters I, Kuczyk MA, Ligges U, Gschwend JE, Retz M, Schmid SC, Stenzl A, Schwentner C, Todenhöfer T, Stöckle M, Ohlmann CH, Azone I, Mager R, Bartsch G, Haferkamp A, Heidenreich A, Piper C, Merseburger AS.

Is there an anti-androgen withdrawal syndrome for enzalutamide?

World J Urol. 2014 Oct;32(5):1171-6. doi: 10.1007/s00345-014-1288-3. Epub 2014 Apr 2. (IF 2.66)

Rausch S, Hennenlotter J, Todenhöfer T, Aufderklamm S, Schwentner C, Sievert KD, Stenzl A, Gakis G.

Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression--introducing a novel prognostic model for bladder cancer recurrence.

Urol Oncol. 2014 Nov;32(8):1178-83. doi: 10.1016/j.urolonc.2014.05.009. Epub 2014 Jun 21. (IF=2.77)

Aufderklamm S, Todenhöfer T, Hennenlotter J, Mischinger J, Böttge J, Halalsheh O, Rausch S, Gakis G, Stenzl A, Schwentner C.

Post-chemotherapy laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors infiltrating the great vessels.

J Endourol. 2014 Jun;28(6):668-74 (IF 1.71)

Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat A.

Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer.

Urol Oncol. 2014 Oct;32(7):1061-8. (IF 2.77)

Sim A, Todenhöfer T, Aufderklamm S, Rausch S, Mischinger J, Halalsheh O, Stenzl A, Bier S, Böttge J, Gakis G, Schwentner C.

Totally intracorporeal replacement of the ureter using whole-mount ileum.

J Endourol. 2014 Oct;28(10):1165-7 (IF 1.71)

Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ.

Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer.

Urol Oncol. 2014 Oct;32(7):1069-77 (IF 2.77)

Aufderklamm S, Todenhöfer T, Hennenlotter J, Mischinger J, Sim A, Böttge J, Rausch S, Bier S, Halalsheh O, Stenzl A, Gakis G, Schwentner C.

[Complex residual tumors after chemotherapy of nonseminomatous germ cell tumors : Laparoscopic management - limits and chances.]

Urologe A. 2014 Oct 3. [Epub ahead of print] (IF 0.44)

Horstmann M, Banek S, Gakis G, Todenhöfer T, Aufderklamm S, Hennenlotter J, Stenzl A, Schwentner C; UroScreen study group.

Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study.

Springerplus. 2014 Jan 13;3:24. doi: 10.1186/2193-1801-3-24. eCollection 2014.

2013

Todenhöfer T, Hennenlotter J, Schmiedel BJ, Hohneder A, Grimm S, Kühs U, Salih HR, Bühring HJ, Fehm T, Gakis G, Blumenstock G, Aufderklamm S, Schilling D, Stenzl A, Schwentner C.

Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases.

Prostate. 2013 Jan;73(2):162-8. (IF 3.56)

Todenhöfer T, Hennenlotter J, Kühs U, Gerber V, Gakis G, Vogel U, Aufderklamm S, Merseburger A, Knapp J, Stenzl A, Schwentner C.

Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?

World J Urol. 2013 Apr;31(2):345-50 (IF 3.423)

Todenhöfer T, Hennenlotter J, Esser M, Mohrhardt S, Tews V, Aufderklamm S, Gakis G, Kühs U, Stenzl A, Schwentner C.

Combined Application of Cytology and Molecular Urine Markers to Improve the Detection of Urothelial Carcinoma

Cancer Cytopathol. 2013 May;121(5):252-60. (IF 3.8)

Todenhöfer T, Stenzl A, Schwentner C.

Optimal use and outcomes of orthotopic neobladder reconstruction in men and women.

Curr Opin Urol. 2013 Sep;23(5):479-86. (IF 2.11)

Todenhöfer T, Hennenlotter J, Aufderklamm S, Kühs U, Gakis G, Germann M, Stenzl A, Schwentner C.

Individual risk assessment in bladder cancer patients based on a multi-marker panel.

J Cancer Res Clin Oncol. 2013 Jan;139(1):49-56. (IF 3.00)

Todenhöfer T, Hennenlotter J, Tews V, Gakis G, Aufderklamm S, Kuehs U, Stenzl A, Schwentner C.

Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma.

Urol Oncol 2013 Oct;31(7):1148-54. (IF=3.64)

Horstmann M, Todenhöfer T (contributed equally), Hennenlotter J, Aufderklamm S, Mischinger J, Kuehs U, Gakis G, Stenzl A, Schwentner C.

Influence of age on false positive rates of urine-based tumor markers.

World J Urol. 2013 Aug;31(4):935-40 (IF 3.423)

Schwentner C, Todenhöfer T, Seibold J, Alloussi SH, Mischinger J, Aufderklamm S, Stenzl A, Gakis G.

Endoscopic inguinofemoral lymphadenectomy--extended follow-up.

J Endourol. 2013 Apr;27(4):497-503 (IF 2.09)

Schwentner C, Todenhöfer T, Seibold J, Alloussi S, Aufderklamm S, Mischinger J, Stenzl A, Gakis G.

Cost effective laparoendoscopic single-site surgery with a reusable platform.

JSLS. 2013 Apr-Jun;17(2):285-91. doi: 10.4293/108680813X13654754534477. (IF 0.81)

Banek S, Schwentner C, Täger D, Pesch B, Nasterlack M, Leng G, Gawrych K, Bonberg N, Johnen G, Kluckert M, Gakis G, Todenhöfer T, Hennenlotter J, Brüning T, Stenzl A; UroScreen Study Group.

Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer:

Results from the UroScreen-Study.

Urol Oncol. 2013 Nov;31(8):1656-62. (IF 3.64)

Lippka Y, Patschan O, Todenhöfer T, Schwentner C, Gutzeit A, Merseburger AS, Horstmann M.

Bladder cancer discussed on the internet: a systematic analysis of gender differences of initial posters on an online discussion board.

Springerplus. 2013 Sep 8;2:445. doi: 10.1186/2193-1801-2-445. eCollection 2013.

Aufderklamm S, Todenhöfer T, Hennenlotter J, Gakis G, Mischinger J, Mundhenk J, Germann M, Stenzl A, Schwentner C.

Bilateral Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection in Nonseminomatous Germ Cell Tumors-a Comparison to Template Dissection.

J Endourol. 2013 Jul;27(7):856-61. (IF 2.09)

Aufderklamm S, Todenhöfer T, Hennenlotter J, Gakis G, Mischinger J, Mundhenk J, Germann M, Stenzl A, Schwentner C.

Post-chemotherapy laparoscopic retroperitoneal lymph node dissection in low volume residual germ cell cancer : A technique to reduce morbidity.

Urologe A. 2013 Aug;52(8):1097-103 (IF 0.43)

Schwentner C, Todenhöfer T, Seibold J, Alloussi S, Germann M, Aufderklamm S, Mischinger J, Stenzl A, Gakis G.

Laparoendoscopic single-site surgery in urology using reusable systems.

Urologe A. 2013 Jan;52(1):54-9. (IF 0.43)

von Au A, Vasel M, Kraft S, Sens C, Hackl N, Marx A, Stroebel P, Hennenlotter J, Todenhöfer T, Stenzl A, Schott S, Sinn HP, Wetterwald A, Bermejo JL, Cecchini MG, Nakchbandi IA.

Circulating fibronectin controls tumor growth

Neoplasia. 2013 Aug;15(8):925-38. (IF 5.39)

Petkova N, Hennenlotter J, Sobiesiak M, Todenhöfer T, Scharpf M, Stenzl A, Bühring HJ, Schwentner C.

Surface CD24 distinguishes between low differentiated and transit-amplifying cells in the basal layer of human prostate.

Prostate. 2013 Oct;73(14):1576-90 (IF 3.56)

Mundhenk J, Hennenlotter J, Alloussi S, Selbherr D, Martzog JC, Todenhöfer T, Kruck S, Schwentner C, Stenzl A, Schilling D.

Influence of body mass index, surgical approach and lymphadenectomy on the development of symptomatic lymphoceles after radical prostatectomy.

Urol Int. 2013; 90(3):270-6. (IF 1.15)

2012

Todenhöfer T, Hennenlotter J, Witstruk M, Kühs U, Aufderklamm S, Gakis G, Stenzl A, Schwentner C.

Influence of Renal Excretory Function on the Performance of Urine-Based Markers for the Detection of Bladder Cancer.

J Urol. 2012 Jan;187(1):68-73. (IF 3.69)

Todenhöfer T, Schwentner C, Stenzl A.

Personalized Treatment of Prostate Cancer Based on Inherited Variations of Steroid Pathway-Related Genes.

Eur Urol. 2012 Jul;62(1):97-9. (IF=10.47)

Todenhöfer T, Hennenlotter J, Feyerabend S, Aufderklamm S, Mischinger J, Kühs U, Gerber V, Fetisch J, Schilling D, Hauch S, Stenzl A, Schwentner C.

Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients.

Anticancer Res. 2012 Aug;32(8):3507-13. (IF 1.71)

Todenhöfer T, Hennenlotter J, Kühs U, Tews V, Gakis G, Aufderklamm S, Stenzl A, Schwentner C.

Influence of urinary tract instrumentation and inflammation on the performance of urinemarkers for the detection of bladder cancer.

Urology. 2012 Mar;79(3):620-5. (IF=2.42)

Todenhöfer T, Schwentner C.

Reply from the authors

Urology. 2012 Mar;79(3):625. (IF=2.42)

Todenhöfer T, Wirths S, von Weyern CH, Heckl S, Horger M, Hennenlotter J, Stenzl A, Kanz L, Schwentner C.

Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma.

BMC Urol. 2012 Mar 21;12(1):7. (IF=1.69)

Todenhöfer T, Renninger, M, Schwentner C, Stenzl A, Gakis G.

A new prognostic model for cancer-specific survival after radical cystectomy including

pre-treatment thrombocytosis and standard pathologic risk factors.

BJU Int. 2012 Dec;110(11 Pt B):E533-40. (IF 3.05).

Schilling D, Todenhöfer T (contributed equally), Hennenlotter J, Schwentner C, Fehm T, Stenzl A.

Isolated, disseminated and circulating tumour cells in prostate cancer.

Nat Rev Urol. 2012 Aug;9(8):448-63 (IF 4.79)

Aufderklamm S, Hennenlotter J, Todenhöfer T (contributed equally) Pilia I, Anastasiadis A, Stenzl A, Schwentner C.

Primary treatment for localized prostate cancer : Evaluation of patients' quality of life.

Urologe A. 2012 May;51(5):713-8. (IF 0.46)

Schwentner C, Todenhöfer T, Seibold J, Alloussi SH, Aufderklamm S, Mischinger J, Germann M, Stenzl A, Gakis G.

Upper Urinary Tract Laparoendoscopic Single-Site Surgery Based on a Novel Cost-Effective Reusable Platform.

J Endourol. 2013 Feb;27(2):202-7. (IF 2.07)

Heni M, Hennenlotter J, Scharpf M, Lutz SZ, Schwentner C, Todenhöfer T, Schilling D, Kühs U, Gerber V, Machicao F, Staiger H, Häring HU, Stenzl A (2012) . Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer. PLoS One. 2012;7(12):e50953. (IF 3.73)

Gakis G, Schwentner C, Todenhöfer T, Stenzl A. (2011).

The current status of molecular markers for prognostication and outcome in invasive bladder cancer.

BJU Int. 2012 Jul;110(2):233-7 (IF 3.05)

Aufderklamm S, Hennenlotter J, Todenhoefer T, Gakis G, Schilling D, Vogel U, Kuehs U, Dlugosch J, Knapp J, Merseburger A, Gerber V, Ordelheide A, Hevler J, Stenzl A, Schwentner C.

XPA-210 - a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence.

World J Urol. 2012 Aug;30(4):547-52 (IF 2.89)

Aufderklamm S, Todenhöfer T, Gakis G, Kruck S, Hennenlotter J, Stenzl A: Schwentner C.

Thymidine kinase and cancer monitoring.

Cancer Lett. 2012 Mar;316(1):6-10 (IF 4.26)

Gakis G, Schwentner C, Todenhöfer T, Stenzl A.

The current status of molecular markers for prognostication and outcome in invasive bladder cancer

BJU Int. 2012 Jul;110(2):233-7 (IF 3.05)

2011

Todenhöfer T, Schwentner C, Gakis G, Schilling D, Stenzl A.

Treatment of metastatic bone disease and treatment-induced osteoporosis in prostate cancer. Evolution of osteoprotective strategies.

Urologe 2011 50(9): 1055-63 (IF=0.33)

Todenhoefer T, Gakis G, Schilling D, Feil G‌, Schwentner C & Stenzl A.

Diagnosis and treatment of prostate cancer-related bone disease.

Clinical Investigation 2011, Vol. 1, No. 2, 265-283

Gakis G, Todenhöfer T (contributed equally), Stenzl A. (2011)

The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer.

Current opinion in Urology 2011 Sep;21(5):428-33. (IF 2.59)

Schilling D, Todenhöfer T, Taran FA, Hartkopf A, Stenzl A, Fehm T.

Mechanisms of Tumour Cell Dissemination and Methods for Detection of Circulating Tumour Cells in Transitional Cell Carcinoma.

Aktuelle Urologie 2011 Mar;42(2):122-127. (IF 0.27)

Gakis G, Todenhöfer T, Renninger M, Schilling D, Schwentner C, Sievert KD, Stenzl A.

A new outcome prediction model in invasive bladder cancer based on preoperative serum c-reactive protein and standard pathologic risk factors: The TNR-C score.

BJU Int. 2011 Dec;108(11):1800-5. (IF 2.84)

Schwentner C, Todenhöfer T, Mundhenk J, Horstmann M, Stenzl A, John H.

Robotic Laparoscopic Cystectomy: On the Way to a Standard Procedure?

Aktuelle Urologie. 2011 Mar;42(2):103-108. (IF 0.27)

Schwentner C, Todenhoefer T, Aufderklamm S, Gakis G, Alloussi SH, Schilling D, Seibold J.

Reply to letter to the Editor

Urology 2011 Sep;78(3): 700 (IF 2.43)

Hennenlotter J, Huber S, Todenhöfer T, Kühs U, Schilling D, Aufderklamm S, Gakis G, Schwentner C, Stenzl A (2011)

Point-of-care tests for bladder cancer – The influencing role of hematuria.

Adv Urol. 2011;2011:937561.

Schwentner C, Czyz J, Seibold J, Todenhoefer T, Alloussi SH, Klocker H, Gakis G, Stenzl A, Baka-Ostrowska M, Radmayr C.

Long-term biochemical evaluation of the androgen receptor pathway in males with disorders of sex development.

World J Urol. 2011 Oct;29(5):677-82. (IF 2.41)

Seibold J, Werther M, Todenhöfer T, Aufderklamm S, Alloussi SH, Schilling D, Gakis G, Stenzl A, Schwentner C.

Urethral ultrasound as a screening tool for stricture recurrence after oral mucosa graft urethroplasty.

Urology 2011 78(3): 696-700. (IF 2.43)

Mundhenk J, Hennenlotter J, Zug L, Alloussi SH, Todenhoefer T, Gakis G, Aufderklamm S, Scharpf M, Kuehs U, Stenzl A, Schwentner C.

Evidence for PTEN-independent Akt activation and Akt-independent p27(Kip1) expression in advanced bladder cancer.

Oncol Lett. 2011 Nov;2(6):1089-1093 (IF 0.11)

Kongressbeiträge auf internationalen Kongressen (Listung: Erstautor oder Letztautor)

2017

Bier S., Hennenlotter J., Beger G., Pavlenco L., Feniuk N., Hauch S., Rausch S., Stenzl A., Todenhöfer T.

Expression analysis of tumor promoting genes in circulating tumor cells of patients with localized and metastatic prostate cancer

AUA Annual Meeting Boston 2017

Schnürer S., Hennenlotter J., Dockter K., Rausch S., Stenzl A., Todenhöfer T.

Does smoking influence the performance of urine markers in the diagnosis of urothelial carcinoma?

EAU Annual Meeting London 2017

Todenhöfer T, Vandekerkhove G., Struss W., Annala M., Beja K., Eigl B., Mischinger J., Stenzl A., Black P., Wyatt A. Using liquid biopsy to assess the genomic landscape of metastatic urothelial carcinoma.

EAU Annual Meeting London 2017

Seiler R., Black P., Thalmann G., Stenzl A., Todenhöfer T.

Clinical and outcome characteristics of the cancer genome atlas (TCGA) bladder cancer cohort: Is it representative?

EAU Annual Meeting London 2017

Bier S., Hennenlotter J., Beger G., Pavlenco L., Feniuk N., Hauch S., Rausch S., Stenzl A., Todenhöfer T.

Expression of tumor progression-associated genes in circulating tumor cells of patients with different stages of prostate cancer

EAU Annual Meeting London 2017

2016

Todenhöfer T., Seiler R., Stewart C., Moskalev I., Gao J., Ladar S., Kamjabi A., Al Nakouzi N., Hayashi T., Choi S., Wang Y.Z., Frees S., Daugaard M., Oo H., Hennenlotter J., Bedke J., Fazli L., Stenzl A., Black PC.

Targeting lactate transporters for the treatment of urothelial carcinoma

EAU Annual Meeting Munich 2016

Todenhöfer T., Kamyabi A., Hennenlotter J., Seiler R., Mcdonald P., Moskalev I., Stewart C., Gao J., Bedke J. , Ooh H.Z., Fazli L., Dedhar S., Stenzl A., Black P.

Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma

EAU Annual Meeting Munich 2016

Todenhöfer T*, Azad A*, Gao J, Stewart C, Eigl B, Black P, Joshua A, Chi KN

ARV7 detected by a novel whole-blood RT-PCR assay correlates with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI)

EAU Annual Meeting Munich 2016 (*contributed equally)

Todenhöfer T. , Volik S. , Eigl B. , North S. , Brahmbhatt S. , Haegert S., Mischinger J., Stenzl A., Le Bihan S. , Collins C., Black P.C.

Non-invasive characterization of metastatic urothelial carcinoma by next-generation sequencing of cell free DNA

EAU Annual Meeting Munich 2016

Schanz M., Hennenlotter J., Dlugosch J., Kuehs U., Dettmer M., Schilling D., Schwentner C., Stenzl A., Todenhöfer T.

Intratumoral heterogeneity of mTOR-pathway parameters in prostate cancer

EAU Annual Meeting Munich 2016

Todenhöfer T*, Azad A*, Gao J, Stewart C, Eigl B, Black P, Joshua A, Chi KN

Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI).

2016 Genitourinary Cancers Symposium American Society of Clinical Oncology (ASCO), San Francisco (*Contributed equally)

2015

Todenhöfer T , Park E, Abdi H, Li A, Ross R, Deng, X., Jin C., Duffy S., Gleave M., Ma H., Black P.C.,

Enrichment of circulating tumor cells in patients with clinically localized

prostate cancer using a microfluidic device

Annual Meeting of the AUA 2015, New Orleans

Todenhöfer T, Hennenlotter J, Faber F, Wallwiener D, Schilling D, Kühs U, Aufderklamm S, Bier S, Mischinger J, Gakis G, Fehm T, Stenzl A, Schwentner C.

Detection of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow at the time of radical prostatectomy

Annual Meeting of the AUA 2015, New Orleans

Todenhöfer T., Hennenlotter J., Dorner N., Beger G., Gerber V., Aufderklamm S, Bier S., Gakis G., Rausch S., Mischinger J., Schellbach D., Feniuk N., Stenzl A., Schwentner C.

Detection of circulating tumor cells in patients with bladder cancer using a breast cancer specific platform reveals a common molecular background

Annual Meeting of the AUA 2015, New Orleans

2014

Todenhöfer T., Leidenberger P., Hennenlotter J., Kühs U., Hohneder A., Aufderklamm S., Stenzl A., Schwentner C.

Systemic alterations of Wnt Inhibitors in patients with prostate cancer and bone metastases

EAU Annual Meeting Stockholm 2014

Todenhöfer T., Hennenlotter J., Kühs U., Esser M., Mohrhardt S., Aufderklamm S. , Gakis G., Stenzl A. , Schwentner C.

Improving diagnostic performance of the UroVysion® assay by using modified criteria for a positive test result

Annual Meeting of the AUA 2014, Orlando

Todenhöfer T., Hennenlotter J., Kühs U., Esser M., Mohrhardt S., Aufderklamm S. , Gakis G., Stenzl A. , Schwentner C.

Positive urine markers predict recurrence in patients with negative cystoscopy during surveillance for bladder cancer

Annual Meeting of the AUA 2014, Orlando

2013

Todenhöfer T., Hennenlotter J., Kühs U., Mohrhardt S., Esser M.,

Aufderklamm S., Mundhenk J., Gakis G., Stenzl A., Schwentner C.

Expedient combination of urine markers enhances their diagnostic performance in the detection of urothelial carcinoma

EAU Annual Meeting Milan 2013

Todenhöfer T., Hennenlotter J., Ritter R., Hoffmann U., Blutbacher P., Deja A., Hohneder A., Stenzl A., Schwentner C.

Point-of-care testing for bladder cancer – the UBC Rapid test on the concile® Ω100 reader platform provides quantitative results

EAU Annual Meeting Milan 2013

Todenhöfer T., Hennenlotter J., Wald A., Leidenberger P., Blumenstock G., Aufderklamm S., Mundhenk J., Gakis G., Kühs U., Hohneder A., Stenzl A.1, Schwentner C.

RANKL pathway proteins as risk parameters for biochemical recurrence in patients undergoing radical prostatectomy

EAU Annual Meeting Milan 2013

Todenhöfer T., Renninger M., Al-Matar B., Abdelhafez M.F., Stenzl A., Gakis G.

External validation of a multicenter prognostic model for risk stratification in pT2N0 bladder cancer

EAU Annual Meeting Milan 2013

Todenhöfer T., Hennenlotter J., Kühs U., Esser M., Mohrhardt S., Aufderklamm S., Mundhenk J. ,Gakis G., Stenzl A. , Schwentner C.

Stepwise application of immunocytology and FISH in the surveillance of patients with non-muscle invasive Bladder cancer

Annual Meeting of the AUA 2013, San Diego

Todenhöfer T., Hennenlotter J., Kühs U., Esser M., Mohrhardt S., Aufderklamm S., Mundhenk J. ,Gakis G., Stenzl A. , Schwentner C.

Urinary Markers for the Detection of Upper Urinary Tract Urothelial Carcinoma – The Value of invasive Urine Sampling

Annual Meeting of the AUA 2013, San Diego

Todenhöfer, T.; Hennenlotter, J.; Kühs, U.; Mohrhardt, S.; Esser, M.; Stenzl, A.; Aufderklamm, S., Schwentner, C.;

Sequentielle Anwendung von Immunzytologie und Fluoreszenz in-situ Hybridisierung in der Nachsorge von Patienten mit nicht-muskelinvasivem Blasenkarzinom

Kongress der deutschen Gesellschaft für Urologie 2013

Todenhöfer, T.; Hennenlotter, J.; Esser, M.; Mohrhardt, S.; Kühs, U.; Aufderklamm, S.; Stenzl, A.; Schwentner, C.,

Urinmarker zur Detektion des Urothelkarzinoms des oberen Harntraktes – Mittelstrahlurin vs. selektiv entommener Urin aus dem oberen Harntrakt

Kongress der deutschen Gesellschaft für Urologie 2013

2012

Todenhöfer T., Hennenlotter J., Kühs U., Gerber V., Aufderklamm S., Gakis G., Stenzl A., Schwentner C.

Farnesyl pyrophosphate synthase – the target enzyme of zoledronic acid is increasingly expressed in prostate cancer tissue

EAU Annual Meeting Paris 2012

Todenhöfer T., Renninger M., Schilling D., Schwentner C., Stenzl A., Gakis G.

External validation of current nomograms in invasive bladder cancer and proposal of a new prognostic models for survival after radical cystectomy based on preoperative haematological disorders

EAU Annual Meeting Paris 2012

Todenhöfer T., Renninger M., Mundhenk J., Abdelhafez M.F., Stenzl A., Gakis G.

Elevated Lactate-dehydrogenase level and positive frozen section analysis are independent risk factors for positive final urethral margins at radical cystectomy

EAU Annual Meeting Paris 2012

Todenhöfer T., Hennenlotter J., Feyerabend S., Kühs U., Aufderklamm S., Fetisch J., Gakis G., Stenzl A., Schwentner C.

PCR-based detection of circulating tumor cells in prostate cancer - preliminary experience

EAU Annual Meeting Paris 2012

Todenhöfer T., Hennenlotter J, Hohneder A., Grimm S., Schmiedel B., Bühring H.J., Gakis G., Stenzl A., Schwentner C..

Evidence for an early interaction of the RANKL pathway and mesenchymal stromal cells in bone marrow of patients with localized prostate cancer

EAU Annual Meeting Paris 2012

Todenhöfer T., Hennenlotter J., Witstruk M., Gakis G., Aufderklamm S., Kühs U., Stenzl A., Schwentner C.

Increased rates of false positive urine based bladder cancer markers due to impaired renal function

EAU Annual Meeting Paris 2012

Todenhöfer T., Hennenlotter J. , Kühs U. , Aufderklamm S., Gerber V., Vogel U., Stenzl A. , Schwentner C.

Altered expression of farnesyl pyrophosphate synthase in prostate cancer - evidence for a role of the mevalonate pathway for disease progression

Annual Meeting of the AUA 2012, Atlanta

Todenhöfer T., Hennenlotter J., Feyerabend S., Kühs U., Aufderklamm S., Fetisch J., Gakis G., Stenzl A., Schwentner C.

Die klinische Bedeutung von zirkulierenden Tumorzellen beim kastrationsresistenten Prostatakarzinom- erste Erfahrungen mit dem Adnatest® System